# Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

> **NCT02455297** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Copanlisib (BAY80-6946)

## Key facts

- **NCT ID:** NCT02455297
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-24
- **Primary completion:** 2016-04-08
- **Final completion:** 2016-08-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02455297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02455297, "Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02455297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*